From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Ibudilast (brand names Ketas or Pinatos in Japan, drug development names AV411 and MN166 the United States)) is a drug used for over 20 years in Japan, mostly for asthma and post-stroke dizziness.[1] Ibudilast is a phosphodiesterase inhibitor, an immunomodulator, reduces microglial activation, and has anti-inflammatory effects.[1]

Potential uses[edit | edit source]

Ibudilast is under investigation for a number of new purposes, and evidence exists that it can be combined with opioids to reduce chronic nerve pain.[1] Many studies of ibudilast are on rats or other animals rather than humans.[1] Ibudilast crosses the blood-brain barrier and suppresses glial cell activation.

Theory[edit | edit source]

Evidence[edit | edit source]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 1.2 1.3 Rolan, P; Hutchinson, MR; Johnson, KW (December 2009). "Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease". Expert Opinion on Pharmacotherapy. 10 (17): 2897–2904. doi:10.1517/14656560903426189. ISSN 1465-6566.